Jadon Deepak R, Chandran Vinod, Ogdie Alexis, Pennington Stephen R, Stober Carmel, Gladman Dafna D, de Wit Maarten, O'Sullivan Denis, Mease Philip, Armstrong April W, Callis Duffin Kristina, Magee Conor, Helliwell Philip, Ritchlin Christopher T, FitzGerald Oliver
From the Rheumatology Research Unit, Cambridge University Hospitals National Health Service (NHS) Foundation Trust, Cambridge; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Bradford Hospitals NHS Foundation Trust, Bradford, UK; Department of Medicine, Division of Rheumatology, University of Toronto; Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Swedish Medical Center/Providence-St. Joseph Health, Seattle, Washington; University of Southern California, Los Angeles, California; University of Utah, Salt Lake City, Utah; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Conway Institute for Biomolecular Research, University College Dublin; Our Lady's Hospice and Care Services; Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland; Department of Medical Humanities, Amsterdam University Medical Center, Amsterdam, the Netherlands.
D.R. Jadon, MBBCh, MRCP, PhD, Director of Rheumatology Research Unit, Cambridge University Hospitals NHS Foundation Trust; V. Chandran, MBBS, MD, DM, PhD, Department of Medicine, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Krembil Research Institute; A. Ogdie, MD, Assistant Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania; S.R. Pennington, Professor of Proteomics, PhD, Conway Institute for Biomolecular Research, University College Dublin; C. Stober, PhD, MBChB, MRCP, Consultant Rheumatologist, Cambridge University Hospitals NHS Foundation Trust; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, Toronto Western Hospital; M. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, Amsterdam University Medical Center; D. O'Sullivan, BE, Patient Research Partner, Our Lady's Hospice and Care Services; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence-St. Joseph Health; A.W. Armstrong, MD, MPH, University of Southern California; K. Callis Duffin, MD, University of Utah; C. Magee, MB, BAO, BCh, St. Vincent's University Hospital; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Bradford Hospitals NHS Foundation Trust; C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin. Professor O. FitzGerald and Professor C.T. Ritchlin are joint senior authors.
J Rheumatol Suppl. 2019 Jun;95:11-19. doi: 10.3899/jrheum.190118.
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-Collaborative Research Network (CRN) intends to launch and secure funding for 3 pilot projects related to psoriatic disease, psoriatic arthritis (PsA), and cutaneous psoriasis (PsC). The first pilot project, a PsA Biomarkers for Joint Damage (BioDAM) pilot, will seek to determine the independent predictive ability of serum biomarkers for joint damage in PsA. The second pilot project will aim to identify predictors of the development of PsA among patients with PsC. The third pilot project will aim to identify biomarkers that predict treatment response in PsA and PsC. These pilot projects will prompt the development of clinical protocols to operate across participating centers, lead to the development of standard operating procedures for the collection and transport of biosamples across international borders, and begin to establish administrative and managerial structures for the CRN. The CRN hopes that the successful completion and research outputs of these 3 pilot projects will demonstrate the CRN's value to prospective collaborators and sponsors and thereby secure sustainable longterm funding.
银屑病和银屑病关节炎研究与评估小组（GRAPPA）协作研究网络（CRN）计划启动并为3个与银屑病、银屑病关节炎（PsA）和皮肤银屑病（PsC）相关的试点项目争取资金。第一个试点项目是银屑病关节炎关节损伤生物标志物（BioDAM）试点项目，旨在确定血清生物标志物对PsA关节损伤的独立预测能力。第二个试点项目旨在确定PsC患者中PsA发病的预测因素。第三个试点项目旨在识别预测PsA和PsC治疗反应的生物标志物。这些试点项目将推动跨参与中心的临床方案的制定，促成跨国界生物样本采集和运输标准操作程序的开发，并开始为CRN建立行政管理结构。CRN希望这3个试点项目的成功完成和研究成果能够向潜在的合作者和赞助商展示CRN的价值，从而获得可持续的长期资金。
